Cargando…

Evaluation of ITGB1 expression as a predictor of the therapeutic effects of immune checkpoint inhibitors in gastric cancer

BACKGROUND: Gastric cancer (CC) is a disease with high incidence and mortality rate. Immunotherapy is an important method for gastric cancer while lack of effective predictor. Integrins play an important role in the development. We aimed to explore the predictive value of β1 integrin (ITGB1) as a pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Chao, Xie, Xiao-Li, Kang, Ning, Jiang, Hui-Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478479/ https://www.ncbi.nlm.nih.gov/pubmed/37667169 http://dx.doi.org/10.1186/s12876-023-02930-0

Ejemplares similares

Comprehensive Analysis of the Expression and Prognosis for ITGBs: Identification of ITGB5 as a Biomarker of Poor Prognosis and Correlated with Immune Infiltrates in Gastric Cancer
por: Liu, Dongliang, et al.
Publicado: (2022)

ITGB1 as a prognostic biomarker correlated with immune suppression in gastric cancer
por: Gu, Wenchao, et al.
Publicado: (2022)

Resistance to immune checkpoint inhibitors in gastric cancer
por: Liu, Kai, et al.
Publicado: (2023)

ITGB4 as a novel serum diagnosis biomarker and potential therapeutic target for colorectal cancer
por: Jiang, Xia, et al.
Publicado: (2021)

An immune checkpoint score system for prognostic evaluation and adjuvant chemotherapy selection in gastric cancer
por: Wang, Jia-Bin, et al.
Publicado: (2020)

Biomarkers of therapeutic response with immune checkpoint inhibitors
por: Bindal, Poorva, et al.
Publicado: (2021)

Immune checkpoint inhibitors
por: Hui, Enfu
Publicado: (2019)

hTERT mediates gastric cancer metastasis partially through the indirect targeting of ITGB1 by microRNA-29a
por: He, Bing, et al.
Publicado: (2016)

Immune checkpoint inhibitor combination therapy for gastric cancer: Research progress
por: Song, Xiaoxu, et al.
Publicado: (2020)

Machine Learning Predictor of Immune Checkpoint Blockade Response in Gastric Cancer
por: Sung, Ji-Yong, et al.
Publicado: (2022)

ENPEP as a potential predictor of immune checkpoint inhibitor efficacy
por: Wang, Aoyun, et al.
Publicado: (2021)

ITGB1-mediated molecular landscape and cuproptosis phenotype induced the worse prognosis in diffuse gastric cancer
por: Zhu, Xingyu, et al.
Publicado: (2023)

Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2020)

Recent insights into the use of immune checkpoint inhibitors in gastric cancer
por: Rodrigues, Soraia, et al.
Publicado: (2022)

Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer
por: Kang, Byung Woog, et al.
Publicado: (2020)

When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer
por: Kim, Hongsik, et al.
Publicado: (2021)

Expression and prognostic analyses of ITGA11, ITGB4 and ITGB8 in human non-small cell lung cancer
por: Wu, Pancheng, et al.
Publicado: (2019)

EccDNA-oriented ITGB7 expression in breast cancer
por: Yang, Lin, et al.
Publicado: (2022)

Transcriptomic analysis reveals high ITGB1 expression as a predictor for poor prognosis of pancreatic cancer
por: Iwatate, Yosuke, et al.
Publicado: (2022)

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
por: Akinleye, Akintunde, et al.
Publicado: (2019)

miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors
por: Huemer, Florian, et al.
Publicado: (2021)

Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
por: Zou, Wenlu, et al.
Publicado: (2021)

Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
por: Wu, Qing, et al.
Publicado: (2022)

Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis
por: Wang, Xiao‐Hui, et al.
Publicado: (2023)

Integrated profiling identifies ITGB3BP as prognostic biomarker for hepatocellular carcinoma
por: Liang, Qiuli, et al.
Publicado: (2021)

The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
por: Jia, Xiao-Hui, et al.
Publicado: (2020)

Immune checkpoint inhibitors
por: Kroemer, Guido, et al.
Publicado: (2021)

LncRNA ITGB2-AS1 Could Promote the Migration and Invasion of Breast Cancer Cells through Up-Regulating ITGB2
por: Liu, Mengyao, et al.
Publicado: (2018)

Key immune-related gene ITGB2 as a prognostic signature for acute myeloid leukemia
por: Wei, Jie, et al.
Publicado: (2021)

Pathologic Predictors of Response to Treatment of Immune Checkpoint Inhibitor–Induced Kidney Injury
por: Abudayyeh, Ala, et al.
Publicado: (2022)

ITGB3 promotes cisplatin resistance in osteosarcoma tumors
por: Li, Qian, et al.
Publicado: (2023)

Therapeutic potential of DNA methyltransferase inhibitors with immune checkpoint inhibitor therapy in breast cancer
por: Luo, Na, et al.
Publicado: (2018)

Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors
por: Dosset, Magalie, et al.
Publicado: (2020)

Glucose metabolism inhibitor PFK-015 combined with immune checkpoint inhibitor is an effective treatment regimen in cancer
por: Zheng, Jia Bo, et al.
Publicado: (2022)

The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors
por: Jin, Ying, et al.
Publicado: (2020)

Prediction of overall survival and response to immune checkpoint inhibitors: An immune-related signature for gastric cancer
por: Wang, Zheng, et al.
Publicado: (2021)

ITGB1-DT Facilitates Lung Adenocarcinoma Progression via Forming a Positive Feedback Loop With ITGB1/Wnt/β-Catenin/MYC
por: Chang, Ruimin, et al.
Publicado: (2021)

The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors
por: Wheeler, Caroline E., et al.
Publicado: (2023)

Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives
por: Zhang, Zhening, et al.
Publicado: (2020)

Association of inflammatory markers with survival in patients with advanced gastric cancer treated with immune checkpoint inhibitors combined with chemotherapy as first line treatment
por: Wan, Mingyu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1j269m3cr7s4uuslk2i9dkbuee